Our Story

Passion, innovation, courage.

scientist pointing pen at computer

At Celgene, we are committed to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first.

Using cutting-edge technology to discover new treatments is at the forefront of Celgene’s entrepreneurial spirit, coupled with a teamwork-oriented culture and commitment to rare diseases. All of these factors play a crucial role in transforming patient outcomes.

Passion, innovation and courage have been in the company’s genes since its founding. “Our journey to a successful company included unexpected road blocks, the courage of our people to convert those road blocks into opportunities and seize them, the vision to not only overcome obstacles but to transform them into novel approaches and progress,” former Chairman & CEO Sol J. Barer, PhD said. On those principles, Celgene has become a leader in delivering medicine to patients with unmet needs, by digging deeper to resolve unanswered scientific questions and working tirelessly to improve the lives of patients worldwide.

Remo Gujer, Vice President & General Manager for UK and Ireland notes, “In 2006, Celgene took the bold decision to go it alone in Europe because we believed we could maximise the benefit of our innovative therapies for patients with high unmet need. We opened our offices in the UK and Ireland the same year, hiring the best possible talent to realise that vision.”

By taking chances, investing heavily into research and development, and taking a unique perspective, Celgene has been able to offer patients options that can enhance their quality of life.

Whether it’s working to deliver innovative therapies to emerging markets that lack proper infrastructure or doggedly pursuing regulatory approvals to bring new options to treat rare diseases, Celgene employees are committed to putting patients first

Joel Beetsch, Vice President, Global Patient Advocacy, has been impressed by the openness of the company and how the typical limitations of red tape in larger organisations don’t tend to apply at Celgene. “It’s a make-it-happen culture,” he said.

Whether it’s working to deliver innovative therapies to emerging markets that lack proper infrastructure or relentlessly pursuing regulatory approvals to bring new options to treat rare diseases, Celgene employees are committed to putting patients first. If an obstacle arises, colleagues work together to brainstorm and figure out a solution to the issue.

Celgene employees also demonstrate a real commitment to the patient communities with which they are involved. Through our corporate social responsibility programme, WeCare, we drive engagement with charities and patient groups, participating in community action days, marathons, bikeathons and numerous other sporting events for the organisations that we support.

Celgene is committed to conducting business based on integrity, ethics, sound decision making, respect for the environment and behaviours that reflect its corporate culture. They have expanded efforts with the aim of continuous improvement of environmental, social and economic performance. These efforts include new methods for patient support and advocacy, personnel interactions with corporate leadership and support for new programmes in local communities.

For Jonel Schwarz, HR Director at Celgene UK & Ireland, the creative employees who collaborate toward a common goal are the critical Celgene elements—the genes that make up the company. “People are very talented, motivated, and driven to think outside the box and make a difference,” she said. “Everyone is engaged because they believe in the mission. Having the same values, they excel in delivering results.”

The story of Celgene encompasses unexpected opportunities, the courage to seize those opportunities, and the vision to transform those opportunities into progress. Ultimately, Celgene hopes to turn some of the most formidable disease challenges of the 21st century into manageable conditions.


UK-CELG170171a(1)
Date of preparation: July 2018